Abstract:The utility of chemical inhibitors in cytochrome P450 (CYP) reaction phenotyping is highly dependent on their selectivity and potency for their target CYP isoforms. In the present study, 17 inhibitors of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4/5 commonly used in reaction phenotyping were evaluated for their cross-enzyme selectivity in pooled human liver microsomes. The data were evaluated using a statistical desirability analysis to identify (1) inhibitors of superior selectivity for reaction phenotyping and (2) optimal concentrations for each. Among the inhibitors evaluated, α -naphthoflavone, furafylline, sulfaphenazole, tienilic acid, N -benzylnirvanol, and quinidine were most selective, such that their respective target enzymes were inhibited by ~95% without inhibiting any other CYP enzyme by more than 10%. Other commonly employed inhibitors, such as ketoconazole and montelukast, among others, were of insufficient selectivity to yield a concentration that could adequately inhibit their target enzymes without affecting other CYP enzymes. To overcome these shortcomings, an experimental design was developed wherein dose response data from a densely sampled multi-concentration inhibition curve are analyzed by a six-parameter inhibition curve function, allowing accounting of the inhibition of off-target CYP isoforms inhibition and more reliable determination of maximum targeted enzyme inhibition. The approach was exemplified using rosiglitazone N -demethylation, catalyzed by both CYP2C8 and 3A4, and was able to discern the off-target inhibition by ketoconazole and montelukast from the inhibition of the targeted enzyme. This methodology yields more accurate estimates of CYP contributions in reaction phenotyping. SIGNIFICANCE STATEMENT Isoform-selective chemical inhibitors are important tools for identifying and quantifying enzyme contributions as part of a cytochrome P450 (CYP) reaction phenotyping assessment for projecting drug-drug interactions. However, currently employed practices fail to adequately compensate for shortcomings in inhibitor selectivity and the resulting confounding impact on estimates of the CYP enzyme contribution to drug clearance. In this report, we describe a detailed half maximal inhibitory concentration (IC 50 ) study design with 6-parameter modeling approach that yields more accurate estimates of enzyme contribution.

Strategies for the Development of Highly Selective Cytochrome P450 Inhibitors: Several CYP Targets in Current Research.

Strategies for the development of highly selective cytochrome P450 inhibitors: Several CYP targets in current research

Understanding Cytochrome P450 Enzyme Substrate Inhibition and Prospects for Elimination Strategies

CYP1A inhibitors: Recent progress, current challenges, and future perspectives

A practical strategy to develop isoform-selective near-infrared fluorescent probes for human cytochrome P450 enzymes

Targeting Cyclin-Dependent Kinases: From Pocket Specificity to Drug Selectivity

Structural insights into understudied human cytochrome P450 enzymes

Exploring Human CYP4 Enzymes: Physiological Roles, Function in Diseases and Focus on Inhibitors

New Insights into the Structural Features and Functional Relevance of Human Cytochrome P450 2C9. Part I.

Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development

Recent Researches on Anti-tumor Drug Development by Targeting Cytochrome P450

Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication

Structure of cytochrome p450s and personalized drug.

Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.

Strategies of Targeting CYP51 for IFIs Therapy: Emerging Prospects, Opportunities and Challenges.

Current state and future perspectives of cytochrome P450 enzymes for C–H and C=C oxygenation

Multiple machine learning, molecular docking, and ADMET screening approach for identification of selective inhibitors of CYP1B1

Inhibitors and Prodrugs Targeting Cyp1: A Novel Approach in Cancer Prevention and Therapy

Unraveling the Structural Basis of Selective Inhibition of Human Cytochrome P450 3A5

Defining the Selectivity of Chemical Inhibitors Used for Cytochrome P450 Reaction Phenotyping: Overcoming Selectivity Limitations with a Six-Parameter Inhibition Curve-Fitting Approach

Recent Advances in Molecular Fluorescent Probes for CYP450 Sensing and Imaging